Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | July 09, 2026 | July 13, 2026 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,383 |
Ending reported balance
After 2026-07-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 19,000 · Balance 27,383 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 2 · 2026-07-09 · Exercise / conversion · Acquired 112,422 · Balance 139,805 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 3 · 2026-07-09 · Exercise / conversion · Acquired 17,167 · Balance 156,972 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 4 · 2026-07-09 · Sale · Disposed 36,167 · Balance 120,805 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 5 · 2026-07-09 · Sale · Disposed 112,422 · Balance 8,383 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-09 · Exercise / conversion · Disposed 19,000 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F2: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2030-06-01 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-09 · Exercise / conversion · Disposed 112,422 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F3: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.75 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-09 · Exercise / conversion · Disposed 17,167 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F4: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
F2: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
F3: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
F4: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,483 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 32,483 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Jazz Pharmaceuticals plc
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,736 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 12,428 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 10,736 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2022 Filed Jun 7, 2022 00:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000093 · wf-form4_165456048293686.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,313 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 00:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 417 | $121.30 | $50,582.10 |
DisclosureSEC source: 0001765581-21-000131 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| November 16, 2021 Filed Feb 22, 2023 01:19 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011455 · doc4.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested as to 50% of the units on November 16, 2020 and the remaining 50% vested on November 16, 2021. F2 · derivative.expiration_date: The RSUs vested as to 50% of the units on November 16, 2020 and the remaining 50% vested on November 16, 2021. Read SEC document |
| November 16, 2021 Filed Feb 22, 2023 01:19 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011455 · doc4.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000067 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,836 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 23:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 38,895 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0000899243-21-025381 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 6,222 | $0.00 Strike: $63.76 | $0.00 |
DisclosureSEC source: 0001209191-21-038376 · doc4.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 6,222 shares Expires 2031-06-02 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038376 · doc4.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,327 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038036 · doc4.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038036 · doc4.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,475 | $0.00 Strike: $170.74 | $0.00 |
DisclosureSEC source: 0001765581-21-000009 · edgardoc.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,475 Underlying: Ordinary Shares · 6,475 shares Expires 2031-02-24 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest 1/3 on December 1, 2021 and in 24 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000009 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,590 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in equal annual installments over three years measured from the vesting commencement date of December 1, 2020, with 1/3 vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent two years. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031548 · doc4.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576 Underlying: Common Stock · 3,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested as to 50% of the units on November 16, 2020 and the remaining 50% will vest on November 16, 2021, subject to the Reporting Person's continuous service with the Issuer through such vesting date. F2 · derivative.expiration_date: The RSUs vested as to 50% of the units on November 16, 2020 and the remaining 50% will vest on November 16, 2021, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031548 · doc4.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034765 · doc4.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Underlying: Common Stock · 3,253 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F3 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 15,183 | $0.00 Strike: $28.82 | $0.00 |
DisclosureSEC source: 0001209191-20-034765 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Underlying: Common Stock · 15,183 shares Expires 2030-06-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 23:23 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 112,422 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015308 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,422 Underlying: Common Stock · 112,422 shares Expires 2030-06-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 01:59 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 82,878 | $0.00 Strike: $37.45 | $0.00 |
DisclosureSEC source: 0000899243-19-029347 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,878 Underlying: Common Stock · 82,878 shares Expires 2029-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after December 12, 2019, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| May 30, 2019 Filed May 31, 2019 22:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,245 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-19-033735 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,245 Underlying: Common Stock · 27,245 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 22:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 50,044 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001209191-18-057789 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,044 Underlying: Common Stock · 50,044 shares Expires 2028-11-05 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on November 6, 2019, and an additional 1/48 of the shares subject to the option vest each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.